Ruxolitinib as an Effective Treatment for Hemophagocytic Lymphohistiocytosis Secondary to SARS-Cov-2 Infection: A Case Report

BACKGROUND: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome. SARS-CoV-2 infection can induce secondary HLH, as described in previous case reports, but diagnosis and treatment are challenging. CASE STUDY: We described an older male patient diagnosed with HLH...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lina, Zhang, Xiaolin, Huang, Bo, Hou, Yue, Liu, Xinmin, Jiao, Hongmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149062/
https://www.ncbi.nlm.nih.gov/pubmed/37131454
http://dx.doi.org/10.2147/IDR.S384035
_version_ 1785035093661712384
author Wang, Lina
Zhang, Xiaolin
Huang, Bo
Hou, Yue
Liu, Xinmin
Jiao, Hongmei
author_facet Wang, Lina
Zhang, Xiaolin
Huang, Bo
Hou, Yue
Liu, Xinmin
Jiao, Hongmei
author_sort Wang, Lina
collection PubMed
description BACKGROUND: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome. SARS-CoV-2 infection can induce secondary HLH, as described in previous case reports, but diagnosis and treatment are challenging. CASE STUDY: We described an older male patient diagnosed with HLH related to previous SARS-CoV-2 infection. Fever was the only clinical manifestation initially but deterioration in clinical condition and laboratory parameters was observed during hospitalization. He responded poorly to classical therapy but was successfully treated with ruxolitinib. CONCLUSION: Clinicians should be aware of the possibility of HLH secondary to mild SARS-CoV-2 infection and take timely therapeutic measures to inhibit an inflammatory factor storm. Ruxolitinib is a potential choice for COVID-19 related HLH.
format Online
Article
Text
id pubmed-10149062
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-101490622023-05-01 Ruxolitinib as an Effective Treatment for Hemophagocytic Lymphohistiocytosis Secondary to SARS-Cov-2 Infection: A Case Report Wang, Lina Zhang, Xiaolin Huang, Bo Hou, Yue Liu, Xinmin Jiao, Hongmei Infect Drug Resist Case Report BACKGROUND: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome. SARS-CoV-2 infection can induce secondary HLH, as described in previous case reports, but diagnosis and treatment are challenging. CASE STUDY: We described an older male patient diagnosed with HLH related to previous SARS-CoV-2 infection. Fever was the only clinical manifestation initially but deterioration in clinical condition and laboratory parameters was observed during hospitalization. He responded poorly to classical therapy but was successfully treated with ruxolitinib. CONCLUSION: Clinicians should be aware of the possibility of HLH secondary to mild SARS-CoV-2 infection and take timely therapeutic measures to inhibit an inflammatory factor storm. Ruxolitinib is a potential choice for COVID-19 related HLH. Dove 2023-04-26 /pmc/articles/PMC10149062/ /pubmed/37131454 http://dx.doi.org/10.2147/IDR.S384035 Text en © 2023 Wang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Report
Wang, Lina
Zhang, Xiaolin
Huang, Bo
Hou, Yue
Liu, Xinmin
Jiao, Hongmei
Ruxolitinib as an Effective Treatment for Hemophagocytic Lymphohistiocytosis Secondary to SARS-Cov-2 Infection: A Case Report
title Ruxolitinib as an Effective Treatment for Hemophagocytic Lymphohistiocytosis Secondary to SARS-Cov-2 Infection: A Case Report
title_full Ruxolitinib as an Effective Treatment for Hemophagocytic Lymphohistiocytosis Secondary to SARS-Cov-2 Infection: A Case Report
title_fullStr Ruxolitinib as an Effective Treatment for Hemophagocytic Lymphohistiocytosis Secondary to SARS-Cov-2 Infection: A Case Report
title_full_unstemmed Ruxolitinib as an Effective Treatment for Hemophagocytic Lymphohistiocytosis Secondary to SARS-Cov-2 Infection: A Case Report
title_short Ruxolitinib as an Effective Treatment for Hemophagocytic Lymphohistiocytosis Secondary to SARS-Cov-2 Infection: A Case Report
title_sort ruxolitinib as an effective treatment for hemophagocytic lymphohistiocytosis secondary to sars-cov-2 infection: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149062/
https://www.ncbi.nlm.nih.gov/pubmed/37131454
http://dx.doi.org/10.2147/IDR.S384035
work_keys_str_mv AT wanglina ruxolitinibasaneffectivetreatmentforhemophagocyticlymphohistiocytosissecondarytosarscov2infectionacasereport
AT zhangxiaolin ruxolitinibasaneffectivetreatmentforhemophagocyticlymphohistiocytosissecondarytosarscov2infectionacasereport
AT huangbo ruxolitinibasaneffectivetreatmentforhemophagocyticlymphohistiocytosissecondarytosarscov2infectionacasereport
AT houyue ruxolitinibasaneffectivetreatmentforhemophagocyticlymphohistiocytosissecondarytosarscov2infectionacasereport
AT liuxinmin ruxolitinibasaneffectivetreatmentforhemophagocyticlymphohistiocytosissecondarytosarscov2infectionacasereport
AT jiaohongmei ruxolitinibasaneffectivetreatmentforhemophagocyticlymphohistiocytosissecondarytosarscov2infectionacasereport

Ejemplares similares